Study Of Lapatinib In Combination With Paclitaxel In The Treatment Of Newly Diagnosed Inflammatory Breast Cancer
Status:
Completed
Trial end date:
2006-11-01
Target enrollment:
Participant gender:
Summary
This Study was designed to determine how effective and safe a new investigational drug,
lapatinib, is in combination with paclitaxel in treating patients with newly diagnosed
inflammatory breast cancer. Tumor tissue collected pre-treatment, following 14 days of
treatment and at the time of surgical resection will be examined for pathologic response and
biologic activity by IHC (immunohistochemistry) within the tumor. Treatment will consist of
14 days of lapatinib monotherapy followed by 12 weeks of combination therapy with lapatinib
and paclitaxel. Blood samples for hematology and chemistry panels, MUGA/ECHO exams and
physical exams will be performed throughout the study to monitor safety.